華誼騰訊娛樂(00419.HK)預計2021年度來自娛樂及媒體業務分部收入將上升
格隆匯 3 月 29日丨華誼騰訊娛樂(00419.HK)公吿，集團將繼續擴大與策略夥伴間協同合作，在持續發展娛樂及媒體業務的同時積極物色其他具潛力的發展機遇，為集團制定長遠穩健的業務版圖。隨着電影《勝利號》和《迷途羔羊》的上映，加上其他製作中項目如《Extinct》及《Moonfall(中文片名暫譯為》《月球隕落》)等的陸續完成，
集團預計2021年度來自娛樂及媒體業務分部的收入將比2020年度大幅上升。同時，集團亦正積極戰略佈局發展中國境內的醫藥和醫療健康服務等領域。中國是全球最具增長潛力的醫藥和醫療健康服務市場，並隨着中國政府推動的一系列醫療醫藥改革，現已進入行業數字化的快速通道。截至自願公佈日期，集團在發展醫藥和醫療健康服務數字化領域有以下的潛在投資合作項目：
集團現正與潛在合作方商討收購一家開發處方藥新零售平台的初創企業集團控股股權。該初創企業集團擁有實體診所，其營業執照涵蓋範圍包括"互聯網診療"，並擁有《醫療機構執業許可證》、《互聯網藥品資訊服務資格證書》、《資訊系統安全三級等級保護備案證明》等完整的資質，並自行研發一套處方藥新零售系統，將醫生、就診者及實體藥店連接起來，建立一個從醫生開具電子處方至就診者從藥店訂購處方藥、進行線上支付及藥物配送的閉環。
根據智研諮詢發佈的《2020-2026年中國處方藥行業市場經營風險及發展趨勢分析報吿》，2020年醫療機構的處方藥外流(即把處方藥物購買權交予就診者)規模約為人民幣4,000億元-5,000億元，且隨着國家醫療保障局進行帶量採購，外流規模有逐步擴大的趨勢。上述處方藥新零售平台目前主要在陝西及廣西地區運作，未來將積極把握中國醫改的機遇，將處方藥新零售平台快速複製至全國各地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
